Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation  by Inoue, Teruo et al.
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ac-1, Leading to a Potential Reduction
n Restenosis After Coronary Stent Implantation
eruo Inoue, MD, FACC,*† Toshihiko Uchida, MD,† Masashi Sakuma, MD,† Yoshitaka Imoto,‡
asushi Ozeki, PHD,§ Yukio Ozaki, MD,§ Yutaka Hikichi, MD,* Koichi Node, MD*
aga, Koshigaya, Tokyo, and Tamaho, Japan
OBJECTIVES The aim of this study was to confirm clinically a hypothesis that cilostazol inhibits leukocyte
Mac-1, leading to prevention of post-stent restenosis.
BACKGROUND The platelet phosphodiesterase III inhibitor called cilostazol also inhibits alpha-granule
release of P-selectin in platelets. The P-selectin–mediated platelet-leukocyte interaction
promotes activation and upregulation of leukocyte Mac-1 after coronary stenting, which plays
a key role on the mechanism of restenosis. Thus, cilostazol’s potential inhibition of this
process may lead to prevention of restenosis.
METHODS Using flow cytometric analysis of whole blood obtained from the coronary sinus, the
expression of platelet membrane glycoproteins and neutrophil adhesion molecules was
observed in 70 consecutive patients undergoing coronary stenting. The patients were
randomly assigned to either a cilostazol or ticlopidine group before stent placement.
RESULTS The restenosis rate was lower (15% vs. 31%, p  0.05) in the cilostazol group (n  34) than
in the ticlopidine group (n  32). A stent-induced increase in platelet P-selectin (CD62P)
expression and an increase in neutrophil Mac-1 (CD11b) expression were suppressed in the
cilostazol group compared with the ticlopidine group. Angiographic late lumen loss was
correlated with the relative changes in platelet P-selectin and neutrophil Mac-1 at 48 h after
coronary stenting.
CONCLUSIONS Cilostazol may have effects on suppression of P-selectin–mediated platelet activation,
platelet-leukocyte interaction, and subsequent Mac-1–mediated leukocyte activation, which
might lead to a reduced restenosis rate after coronary stent implantation. (J Am Coll
Cardiol 2004;44:1408–14) © 2004 by the American College of Cardiology FoundationP
c
a
a
a
o
a
C
m
P
s
1
a
a
b
p
m
i
(
a
F
p
l
t
cilostazol (6-[4-(l-cyclohexyl-lH-tetrazol-5-yl)butoxy]-
,4-dihydro-2[lH]-quinolinone) is an antiplatelet drug (1)
eveloped in Japan, which has been applied as part of an
ntiplatelet regimen after coronary stenting. Its antiplatelet
ction is mainly due to phosphodiesterase (PDE) III inhi-
ition, which also results in reduced smooth muscle cell
rowth and extracellular matrix synthesis (2,3), and these
dditional effects might be expected to reduce post-stent
estenosis. Indeed, several clinical trials, including our own
andomized trial, have provided data that cilostazol can
ower the restenosis rate (4). However, most of these trials
ere done in the setting of a single-center trial with a small
ample size. More recently, a larger cohort U.S. multicenter
tudy—the Cilostazol for REStenosis Trial (CREST) (5)—
oncluded that cilostazol significantly reduced the rate of
estenosis after coronary stenting. In addition to the anti-
latelet action due to PDE III inhibition, cilostazol also
nhibits activation-dependent alpha-granule release and
From the *Department of Cardiovascular and Renal Medicine, Saga University
aculty of Medicine, Saga; †Department of Cardiology, Koshigaya Hospital, Dokkyo
niversity School of Medicine, Koshigaya; ‡Yufu Itonaga Company, Tokyo; and
Department of Laboratory Medicine, Interdisciplinary Graduate School of Medi-
ine and Engineering, University of Yamanashi, Tamaho, Japan. This study was
upported in part by a grant from the Vehicle Racing Commemorative Foundation,
okyo, Japan.
Manuscript received May 12, 2004; revised manuscript received June 23, 2004,hccepted June 29, 2004.-selectin expression on the surface of platelets (6), and the
linical significance still needs to be clarified in detail.
The activation of leukocytes, neutrophils, and monocytes,
s well as their interaction with platelets mediated by cell
dhesion molecules, are known to play an important caus-
tive role in the development of restenosis after percutane-
us coronary intervention (PCI) (7–10). Among various
dhesion molecules, leukocyte integrin, Mac-1 (CD11b/
D18), is considered to be one of the key proteins in the
echanism of restenosis. Clinical evidence indicates that
CI results in activation and upregulation of Mac-1 on the
urface of neutrophils in association with restenosis (10–
5). In experimental models, Mac-1 blockade (16) or the
bsence of Mac-1 (17) suppressed neointimal thickening
fter PCI. There is increasing evidence that the interaction
etween platelets and leukocytes across an adherent layer of
latelets precedes diapedesis and the infiltration of inflam-
atory cells into the PCI-induced injured vessel wall, which
s denuded of vascular endothelial cells by balloon inflation
18–20). Platelet surface P-selectin mediates the rolling
ttachment of leukocytes with the platelet layer (21,22).
urthermore, Mac-1 is of particular importance in the
rocess of transplatelet migration and firm adhesion of
eukocytes. In the process of the platelet-leukocyte interac-
ion, an adhesion cascade appears to occur with considerable
ross-talk between P-selectin and Mac-1 (20,21). Thus, we
ypothesize that cilostazol’s inhibitory effects on P-selectin–
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October 6, 2004:1408–14 Cilostazol Inhibits Leukocyte Mac-1 After PCIediated platelet-leukocyte interactions would also suppress
eukocyte Mac-1 expression that leads to the prevention of
eointimal thickening and restenosis.
To confirm this hypothesis clinically, we measured the in
ivo expression of Mac-1 on the surface of neutrophils, as
ell as that of P-selectin on the surface of platelets in
atients undergoing coronary stenting, and we compared
wo post-stent antiplatelet regimens—cilostazol and ticlo-
idine. In addition, we also assessed cilostazol’s direct action
n neutrophil Mac-1 expression in an in vitro experiment.
ETHODS
tudy design. The subjects included 70 consecutive pa-
ients with isolated atherosclerotic coronary artery disease of
he proximal left anterior descending coronary artery who
nderwent initial elective single coronary stent implanta-
ion. The patients were randomly assigned to either a
ilostazol or ticlopidine group at least three days before PCI.
he patients assigned to each group started receiving daily
ral cilostazol (200 mg) or ticlopidine (200 mg), both of
hich are standard doses in Japan, in addition to 81 mg
spirin three days before PCI, because ticlopidine requires
wo or three days to reach an effective blood concentration.
ach specific antiplatelet regimen was continued until
ollow-up coronary angiography. Coronary stent implanta-
ion was performed using standard techniques with the
emoral approach, and lesions were assessed by quantitative
oronary angiography. Before PCI, a catheter was posi-
ioned in the coronary sinus and left for 48 h after the
rocedure. Coronary sinus blood was collected via the
oronary sinus catheter before PCI and at 15 min, 24 h, and
8 h after coronary stenting. Whole blood was immediately
ollected into a tube containing acid citrate dextrose. The
tudy protocol was approved by the local ethics committee,
nd written, informed consent was obtained from each
atient.
xpression of activation-dependent P-selectin on surface
f platelets. Flow cytometric analysis of the internal alpha-
ranule membrane protein P-selectin expressed on the surface
f activated platelets was performed using phycoerythrin-
abeled anti-CD62P (Immunotech, Eugene, Oregon).
sotype-, fluorochrome-, and protein concentration-matched
Abbreviations and Acronyms
cAMP  cyclic adenosine monophosphate
CREST  Cilostazol for REStenosis Trial
DMSO  dimethyl sulfoxide
FITC  fluorescein isothiocyanate
FMLP  formyl-methyonyl leucyl phenylalanine
MFI  mean channel fluorescence intensity
PBS  phosphate-buffered saline
PCI  percutaneous coronary intervention
PDE  phosphodiesterase
PSGL  P-selectin glycoprotein ligandontrols were run in parallel for phycoerythrin-labeled immu- Foglobulin G (IgG1) (Dako Cytomation, Glostrup, Den-
ark). Immunofluorescence staining was performed using
inor modifications of previously published procedures.
riefly, 100 l of whole blood was first fixed in 1 ml of 1%
araformaldehyde for 2 h at 4°C. After centrifugation at
0,000 rpm for 1 min, the supernatant was removed, and the
ellets were washed twice with 1 ml of phosphate-buffered
aline (PBS), followed by centrifugation at 10,000 rpm for 1
in. The pellets were then suspended in 1 ml of PBS with
.1% bovine serum albumin and 20 l of each monoclonal
ntibody was added. After incubation in the dark for 15 min at
oom temperature, the samples were washed once more and
uspended in 1 ml of PBS. A FACSCalibur laser flow
ytometry system (BD Bioscience, San Jose, California) was
sed for flow cytometry and calibrated daily with a mixture of
onosized, fluorescent beads (CaliBRITE, BD Bioscience).
e analyzed scatter signals and fluorescence intensity. The
ight-scattering properties projected on a scattergram identified
he platelet cluster. Fluorescence intensity was expressed on
ndividual cytohistograms, with the region of interest limited to
he platelet cluster. The mean channel fluorescence intensity
MFI) was calculated as an index of the expression of
-selectin.
xpression of Mac-1 on surface of neutrophils in vivo. The
xpression of the adhesion molecule, Mac-1, on the surface
f neutrophils was analyzed in the same manner as previ-
usly described. Briefly, whole blood was immediately
ollected into a tube containing acid citrate dextrose. Im-
unofluorescence staining was performed using fluorescein
sothiocyanate (FITC)-labeled anti-CD16b (1D3; Beck-
an Coulter, Fullerton, California) and phycoerythrin-
abeled anti-CD11b (Leu 15; Becton Dickinson). Isotype
ontrols were run in parallel for FITC-labeled IgG1 (BD
ioscience) and phycoerythrin-labeled IgG2a (BD Bio-
cience). After completion of hemolysis by the lysing solu-
ion, the white blood cell sediment was fixed in a parafor-
aldehyde solution with PBS. Flow cytometric analysis was
hen performed using the FACSCalibur laser flow cytom-
ter. We could detect neutrophils as CD16b-positive cells.
xpression of CD11b (Mac-1 specific alpha subunit) on the
urface of neutrophils was detected as MFI of phycoerythrin
uorescence.
n vitro assessment of cilostazol’s direct action on neu-
rophil Mac-1. Blood was collected from seven healthy
olunteers with sodium citrate. After completion of hemo-
ysis, the white blood cells were sedimented, rinsed, and
uspended. Cilostazol was dissolved in dimethyl sulfoxide
DMSO), and 3, 10, and 30 mol/l doses of cilostazol were
o-incubated with the white blood cell suspension and
timulated with 0.05 mol/l of formyl-methyonyl leucyl
henylalanine (FMLP) for 24 h. Both FITC-labeled anti-
D16b and phycoerythrin-labeled anti-CD11b were added
o the white blood cell suspension and incubated. Neutro-
hils were detected as CD16b-positive cells using the
ACSCalibur flow cytometer. Expression of CD11b on the
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Cilostazol Inhibits Leukocyte Mac-1 After PCI October 6, 2004:1408–14urface of neutrophils was detected as MFI of phycoerythrin
uorescence.
tatistical analysis. Data are expressed as the mean value
SD. A comparison of clinical variables between the two
roups was performed using the Mann-Whitney U test for
ontinuous variables and the chi-square test for categorical
ariables. Serial changes in the in vivo variables were
valuated by repeated measures analysis of variance with
unnett’s post-hoc test for intra- and inter-group compar-
sons. In vitro tests were analyzed by the nonparametric
riedman test. Correlations between two parameters were
valuated by simple linear regression. The p values of0.05
ere considered significant.
ESULTS
oronary stenting. Of a total 70 patients, 35 each were
ssigned to the cilostazol and ticlopidine groups, respec-
Table 1. Baseline Characteristics
Cilostaz
Group (n 
Age (yrs) 62.8  3
Men/women 20/14
Diagnosis (AP/OMI) 18/16
Platelet count (104/l) 25.6  2
Leukocyte count (/l) 5,870  1
Risk factors
Family history, n (%) 3 (9)
Smoking, n (%) 27 (79)
Hypertension, n (%) 14 (41)
Diabetes mellitus, n (%) 5 (15)
LDL cholesterol (mg/dl) 124 5
HDL cholesterol (mg/dl) 38 2
Medications
Nitrates 32 (94)
Beta-blockers 11 (32)
Calcium channel blocker 9 (26)
Nicorandil 2 (6)
Aspirin 34 (100
AP  angina pectoris; HDL  high-density lipoprotein; LD
myocardial infarction.
Table 2. Quantitative Coronary Angiographic
C
Grou
Before PCI
Lesion length (mm) 10
Reference dimeter (mm) 3.1
MLD (mm) 1.0
Diameter stenosis (%) 67
After PCI
MLD (mm) 2.8
Diameter stenosis (%) 11
Acute gain (mm) 1.8
Follow-up angiography
MLD (mm) 2.4
Diameter stenosis (%) 21
Late lumen loss (mm) 0.3
Restenosis, n (%)
Target lesion revascularization, n (%)MLD  minimal lumen diameter; PCI  percutaneous coronaryively. A total of four patients subsequently had to be
xcluded from analysis: a patient in the cilostazol group who
nderwent double stenting due to serious balloon-induced
issection occurring before stenting and three patients in
he ticlopidine group who were obliged to discontinue its
dministration due to serious adverse events (liver dysfunc-
ion in two and granulocytopenia in one). Baseline charac-
eristics were similar between the 34 patients in the cilosta-
ol group and the 32 patients in the ticlopidine group who
ere included in the analysis (Table 1). Neither acute nor
ubacute stent thrombosis occurred in any patient in either
roup. No major cardiac events, major bleeding, or other
erious complications were experienced in either group
hroughout the observation period. Quantitative coronary
ngiography results are shown in Table 2. At follow-up
ngiography, the minimal lumen diameter tended to be
arger (2.48  0.13 mm vs. 1.97  0.15 mm, p  0.052)
Ticlopidine
Group (n  32) p Value
63.1  2.3 NS
21/11 NS
17/15 NS
26.4  2.6 NS
5,660  190 NS
3 (9) NS
28 (88) NS
12 (38) NS
6 (19) NS
122  4 NS
38  3 NS
31 (97) NS
10 (31) NS
9 (28) NS
2 (6) NS
32 (100) NS
low-density lipoprotein; NS  not significant; OMI  old
lts
zol
 34)
Ticlopidine
Group (n  32) p Value
.4 9.7  0.5 NS
.11 3.14  0.10 NS
.06 1.04  0.05 NS
.8 66.9  1.5 NS
.12 2.84  0.11 NS
.8 20.1  0.8 NS
.11 1.80  0.09 NS
.13 1.97  0.15 0.052
.6 37.2  4.3 0.056
.07 0.87  0.10 0.028
) 10 (31) 0.048
8 (25) 0.036ol
34)
.2
.2
70
)
L Resu
ilosta
p (n
.2  0
7 0
2  0
.3 1
2  0
.0 0
0  0
8  0
.8 3
4  0
4 (15
2 (6)intervention.
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October 6, 2004:1408–14 Cilostazol Inhibits Leukocyte Mac-1 After PCInd the late lumen loss (minimal lumen diameter after PCI
inus minimal lumen diameter at follow-up angiography)
as smaller (0.74  0.34 mm vs. 1.12  0.47 mm, p 
.05) in the cilostazol group than in the ticlopidine group.
s a result, the restenosis rate (15% vs. 31%, p  0.05) and
he target lesion revascularization rate (6% vs. 25%, p 
.05) were lower in the cilostazol group.
hanges in platelet P-selectin and neutrophil Mac-1
fter stenting. Expression of P-selectin on the surface of
latelets increased after coronary stenting in a time-
ependent manner, reaching a maximum value 48 h after
tenting. These changes were lower in the cilostazol group
han in the ticlopidine group, with the relative increases at
5 min, 24 h, and 48 h, as compared with the baseline values
f 128  14% vs. 161  15%, 124  18% vs. 163  22%,
nd 133 20% vs. 170 27%, respectively (p 0.05) (Fig.
, left).
Serial changes in the expression of CD11b on the surface
igure 1. Serial changes in P-selectin (CD62P) on the surface of platelets (
oronary stenting. Platelet P-selectin and neutrophil Mac-1 increased after
t 48 h. Both changes were suppressed in the cilostazol group compared w
0.001 vs. baseline. †p  0.05 for intergroup comparison. ††p  0.01 for
ticlopidine group (n  32). MFI  mean channel fluorescence intensi
igure 2. Correlation between angiographic late lumen loss and relative ch
8 h after coronary stenting. Open circles  cilostazol group (n  34); solid cf neutrophils were also compared between the cilostazol
nd ticlopidine groups. Although no change was evident 15
in after stenting, the increase was noted after 24 h and
aximally after 48 h in both groups. These changes were
ower in the cilostazol group than in the ticlopidine group,
ith the relative increases at 15 min, 24 h, and 48 h, as
ompared with the baseline values of 103  22% vs. 114 
6%, 125  28% vs.170  44%, and 170  35% vs. 268 
8%, respectively (p  0.01) (Fig. 1, right).
eointimal thickening and cell adhesion molecules. An-
iographic late lumen loss was correlated with relative
hanges in platelet P-selectin (r  0.27, p  0.05) and
eutrophil CD11b (r  0.37, p  0.01) at 48 h after
oronary stenting (Fig. 2).
ilostazol’s direct action on neutrophil Mac-1 in
itro. Cilostazol inhibited the expression of Mac-1
CD11b) on the surface of neutrophils in vitro in a dose-
ependent manner. The relative changes in CD11b expres-
nel) and Mac-1 (CD11b) on the surface of neutrophils (right panel) after
ary stenting in a time-dependent manner, and the maximum increase was
he ticlopidine group. *p  0.05 vs. baseline. **p  0.01 vs. baseline. ***p
roup comparison. Open circles  cilostazol group (n  34); solid circles
in platelet P-selectin (left panel) and neutrophil CD11b (right panel) atleft pa
coron
ith t
interg
ty.anges
ircles  ticlopidine group (n  32).
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Cilostazol Inhibits Leukocyte Mac-1 After PCI October 6, 2004:1408–14ion at 3, 10, and 30 mol/l of cilostazol versus control
DMSO, FMLP) were 102.2  22.0%, 72.9  29.0%,
nd 34.0  27.3%, respectively (Fig. 3).
ISCUSSION
n the present study, the expression of P-selectin on the
urface of platelets increased immediately after coronary
tenting with the increased expression continuing for 48 h
fter PCI. Also, the expression of CD11b increased (i.e.,
ac-1 was upregulated) on the surface of neutrophils 24 to
8 h after PCI, with the maximum increase at 48 h.
oreover, angiographic late lumen loss (i.e., neointimal
hickening) was correlated with relative changes in platelet
-selectin and neutrophil Mac-1 at 48 h after coronary
tenting. In these findings, we observed the kinetics of cell
dhesion molecules in the coronary sinus blood samples but
ot in the peripheral blood samples, so that we assessed local
nflammation and cell activation in the PCI-injured coro-
ary vessels, confirming our previous results. The increases
n platelet P-selectin and neutrophil Mac-1 were lower in
he cilostazol group than in the ticlopidine group. Addi-
ionally, the late lumen loss was smaller in the cilostazol
roup, correlating with both the kinetics of platelet
-selectin and neutrophil Mac-1. These results suggest the
ossibility that cilostazol has beneficial effects on restenosis
eduction, presumably through inhibition of two cell adhe-
ion molecules.
echanisms of cilostazol’s action. Cilostazol acts as a
elective inhibitor of PDE type III, an enzyme that breaks
own cyclic adenosine monophosphate (cAMP). A higher
evel of cAMP stimulates the production of cAMP-
ependent protein kinase, resulting in a lower level of
ntracellular Ca within platelets, which, in turn, sup-
resses platelet activity (23). In addition to PDE III
nhibition, we have observed a previous in vitro study that
ilostazol inhibits an increase in P-selectin expression on the
urface of adenosine diphosphate-stimulated platelets (2).
igure 3. Cilostazol’s direct action for Mac-1 (CD11b). Cilostazol inhib-
ted an expression of Mac-1 on surface of neutrophils in vitro in a
ose-dependent manner, compared with the control (dimethyl sulfoxide
DMSO] formyl-methyonyl leucyl phenylalanine [FMLP]). *p  0.05.
*p  0.01.ere we provide the first in vivo human data showing that lilostazol can inhibit stent-induced P-selectin expression on
latelets, supporting the results of our previous in vitro
xperiments.
In the present study, we also demonstrated that cilostazol
nhibited stent-induced Mac-1 upregulation on the surface
f neutrophils. The activation of leukocytes, neutrophils,
nd monocytes is known to play an important causative role
n the development of restenosis after PCI (7–10). Acti-
ated leukocytes transmigrate and infiltrate into the PCI-
njured vessel wall and produce various cytokines, growth
actors, free radicals, and proteolytic enzymes, leading to
eointimal thickening and restenosis. At the PCI-injured
essel wall, which is denuded of vascular endothelial cells by
he balloon inflation, platelets first adhere to the vessel
urface and the platelet layer is formed. Leukocytes adhere
o the platelet layer and then migrate into the vessel
all—namely, transplatelet leukocyte migration (18–20). In
he process of transplatelet leukocyte migration, platelet
urface P-selectin binds to P-selectin glycoprotein ligand
PSGL)-1 on the surface of leukocytes and mediates the
olling attachment of leukocytes with the platelet layer
21–22). In addition, subsequent firm adhesion of leuko-
ytes is mediated by Mac-1, which is expressed on activated
eukocytes and binds to ligands such as fibrinogen (20,21),
latelet glycoprotein Ib alpha (24), intercellular adhesion
olecule-2 (20), or junctional adhesion molecule-3 (25).
vangelista et al. (21,22) demonstrated in their in vitro
xperiment that the binding of P-selectin to PSGL-1
riggers tyrosine kinase-dependent signaling, which leads to
unctional upregulation or activation of Mac-1. Therefore,
here is an important adhesion cascade between leukocytes
nd platelets, and cilostazol may block this cascade by acting
n platelet P-selectin, as well as leukocyte Mac-1, to inhibit
ross-talk between leukocytes and platelets. In this study, we
ocused on neutrophils but not monocytes based on our
revious observations and the observations of others, that
eutrophils are likely the first cells recruited to the injured
essel. Additionally, in the present study, we observed that
ilostazol directly inhibited neutrophil surface Mac-1 up-
egulated in vitro by FMLP. The mechanism of cilostazol’s
irect inhibitory action for leukocyte Mac-1 is not well
nderstood. Although cilostazol also has nonspecific inhib-
tory action for other PDEs in addition to PDE III, its
nhibitory effect for PDE IV, which is known to be
xpressed in leukocytes, is very weak (26). Thus, we spec-
late that there are some unknown mechanisms indepen-
ent of PDE inhibition. Our results suggest that cilostazol
ay inhibit Mac-1 both through a direct action as well as
hrough inhibition of P-selectin and subsequent P-selectin–
SGL-1 signaling.
There is much evidence that Mac-1 is one of the key
roteins in the mechanism of restenosis. We have demon-
trated clinically that PCI induced activation (15) and
pregulation (11–14) of Mac-1 on the surface of neutrophils
nd that Mac-1 kinetics were linked to angiographic late
umen loss—namely, neointimal thickening (13,14). Rogers
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October 6, 2004:1408–14 Cilostazol Inhibits Leukocyte Mac-1 After PCIt al. (16) demonstrated in the rabbit iliac artery model that
ac-1 blockade by a monoclonal antibody against CD11b
uppressed neointimal thickening after balloon-induced or
tent-induced vessel wall injury. Simon et al. (17) demon-
trated that, in Mac-1–deficient mice, neointimal thicken-
ng after balloon-induced carotid artery injury was sup-
ressed compared with Wild-type mice. Therefore,
hemical, biologic, or pharmacologic approaches targeting
ac-1 (i.e., Mac-1 blockade) are potentially powerful
trategies for the prevention of restenosis.
Cilostazol also has direct inhibitory effects on smooth
uscle cell growth and extracellular matrix synthesis
hrough its PDE III-inhibiting action, which causes an
ncrease of intracellular cAMP and a decrease of 3H-
hymidine uptake (2,3). These effects possibly lead to direct
nhibition of neointimal growth and a reduction in resteno-
is (4,27–29). In addition to the direct inhibition of neoin-
imal growth through the action of PDE III, the results of
he present study suggest that cilostazol may act as a Mac-1
locker, and that this may play a role in the reduction of
estenosis.
tudy limitations. The present study had several potential
imitations. In this study, we investigated the quantity of
ac-1 on the cell surface (upregulation), rather than func-
ional Mac-1 activity using a Mac-1 activation-dependent
ntibody. In our previous study, we assessed the serial
rocess of activation and upregulation of Mac-1 after PCI.
lthough activation of Mac-1 occurred earlier than its
pregulation (15), we confirmed that serial changes in
ctivation and upregulation were parallel and that the
linical significance of both findings was similar. Thus, this
tudy only focused on the simple quantitative assessment of
ac-1. Although we assessed separately platelet P-selectin
nd leukocyte Mac-1 in this study, quantifying the number
f platelet-leukocyte conjugates or the Mac-1 expression on
latelet-bound and non–platelet-bound leukocytes might be
f greater interest to further assess the adhesion cascade in
he process of the platelet-leukocyte interaction with cross-
alk between P-selectin and Mac-1 (30,31). This study
ompared cilostazol with ticlopidine, a therapeutic no
onger in widespread use in the U.S. and European coun-
ries but a standard post-stent antiplatelet regimen in Japan.
ecently, clopidogrel has replaced ticlopidine in Western
ountries (32,33). At present, however, clopidogrel is not
vailable in Japan. The CREST (5) compared the cilostazol
nd placebo groups, both of which were under the baseline
reatments with aspirin and clopidogrel and succeeded in
he reduction of restenosis. Therefore, we can see that
ilostazol prevents restenosis as an additional effect of
lopidogrel.
linical implications. Although the biggest hurdle of
CI—restenosis—has been markedly reduced since the
ntroduction of coronary stents, bare-metal stents cannot
educe restenosis to 20%. On the other hand, recent
dvances in drug-eluting stents, such as the Sirolimus-
oated stent, have further reduced restenosis to 10% (34).ven with the drug-eluting stents, however, small vessel
esions and the complication of diabetes are still weakness
or conquest of restenosis (35). Therefore, the problem of
estenosis remains unresolved, and we should continue
rying to reduce the restenosis rate until it is nearly equal to
ero. The CREST (5) demonstrated by subgroup analysis
hat cilostazol was associated with a significantly lower
estenosis rate, even in patients with small vessel lesions and
n patients with diabetes. Therefore, oral cilostazol would be
powerful strategy for a further reduction of restenosis in
ddition to drug-eluting stents.
Recent chemical, biologic, or pharmacologic approaches
o prevent restenosis are “anti-proliferative” or “anti-
nflammatory” strategies. Cilostazol may represent a hybrid
rug for the prevention of restenosis having both antipro-
iferative (PDE-mediated inhibition of smooth muscle cell
roliferation), as well as anti-inflammatory (inhibition of
eukocyte integrin Mac-1) effects.
onclusions. Cilostazol may have effects for inhibiting
ac-1–mediated leukocyte activation directly or through
-selectin–mediated platelet activation, which may lead to a
eduction in the rate of restenosis after coronary stent
mplantation.
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